Browse

Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: A retrospective analysis

Cited 2 time in Web of Science Cited 2 time in Scopus
Authors
Han, Jung Ho; Park, Chul-Kee; Lee, Se-Hoon; Kim, Chae-Yong; Kim, Dong-Wan; Paek, Sun Ha; Kim, Dong Gyu; Heo, Dae Seog; Kim, Il Han; Jung, Hee-Won
Issue Date
2009-05
Publisher
Karger
Citation
Chemotherapy, Vol.55 No.3, pp.145-154
Keywords
GlioblastomaPreradiation chemotherapyACNUCisplatinSurvival
Abstract
Objective: We evaluated the benefit of preradiation chemotherapy with ACNU (nimustine) and CDDP ( cisplatin) in patients with newly diagnosed glioblastoma by retrospective analysis. Methods: A total of 151 patients were newly confirmed to have glioblastoma between January 2000 and December 2004. All patients underwent surgical resection: 38 (25.2%) patients underwent complete resection, 73 (48.3%) underwent incomplete resection and 40 (26.5%) underwent biopsy. Preradiation chemotherapy using ACNU-CDDP was administered as an initial adjuvant therapy for 87 (57.6%) patients (ACNU-CDDP group), radiation therapy was performed in 31 ( 20.5%) patients (RT group) and the remaining 33 (21.9%) patients were treated with other regimens or refused to undergo further treatment. Results: The median survival time was 13 months (95% CI 11.29-14.71), and the overall survival rate was 54.0% at 1 year and 21.3% at 2 years. The differences in median survival time between the complete resection group and biopsy group and between the ACNU-CDDP group and RT group were significant (15.0 vs. 10 months, p = 0.028, and 16.0 vs. 12.0 months, p = 0.036, respectively) in the univariate analyses. Even in the multivariate analysis, preradiation chemotherapy using ACNU-CDDP had a significant effect on survival prolongation (HR = 0.628, p = 0.042). The usage of temozolomide for adjuvant or salvage therapy also had an independent and significantly positive effect on survival ( HR = 0.511, p = 0.006). Grade 3 and 4 hematologic toxicities occurred in 28 (32.1%) patients in the ACNU-CDDP group, but there were no treatment-related deaths. Conclusion: Preradiation chemotherapy with ACNU-CDDP as an initial therapy for patients with newly diagnosed glioblastoma is feasible and should be assessed in a randomized phase III study. Copyright (C) 2009 S. Karger AG, Basel
ISSN
0009-3157
Language
English
URI
https://hdl.handle.net/10371/74203
DOI
https://doi.org/10.1159/000214142
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse